{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:25:23Z","timestamp":1790144723769,"version":"4.0.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Taxanes, derived from Taxus chinesnsis, stabilize microtubules and include drugs like Paclitaxel, Docetaxel, and Nab-paclitaxel. These are commonly used to treat various malignant tumors. However, Taxane-drug-induced cystoid macular edema (TDICME) is a rare and often under-recognized complication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A male patient, aged sixty-three, who was diagnosed with poorly differentiated gastric adenocarcinoma, experienced a progressive decline in visual acuity in both eyes after a 4-month course of nab-paclitaxel therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Upon Fundus examination, bilateral cystoid macular edema (CME) was seen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Undergo treatment with carbonic anhydrase inhibitors and discontinue the use of nab-paclitaxel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After eleven days of treatment with carbonic anhydrase inhibitors, the patient reported significant improvement in visual acuity. Furthermore, CME was completely resolved in both eyes 8 weeks after stopping nab-paclitaxel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case highlights the potential therapeutic effectiveness of topical carbonic anhydrase inhibitors in treating TDICME. Our findings underscore the importance of monitoring and addressing ocular side effects in patients undergoing Taxane therapy, ultimately contributing to enhanced patient quality of life and treatment outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040958","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T14:04:30Z","timestamp":1736258670000},"page":"e40958","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of topical carbonic anhydrase inhibitors in treating taxane drug-induced cystoid macular edema: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Xianbing","family":"Hou","sequence":"first","affiliation":[{"name":"Fenghua Hospital of Traditional Chinese Medicine, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Chen","sequence":"additional","affiliation":[{"name":"Fenghua Hospital of Traditional Chinese Medicine, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1129","authenticated-orcid":false,"given":"Yingxue","family":"Lu","sequence":"additional","affiliation":[{"name":"Fenghua Hospital of Traditional Chinese Medicine, Ningbo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250909","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"key":"R2-20250909","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/02713683.2011.594202","article-title":"Breast cancer medications and vision: effects of treatments for early-stage disease.","volume":"36","author":"Eisner","year":"2011","journal-title":"Curr Eye Res"},{"key":"R3-20250909","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archopht.126.11.1605","article-title":"Cystoid macular edema secondary to albumin-bound paclitaxel therapy.","volume":"126","author":"Smith","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R4-20250909","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1200\/JCO.2010.30.3750","article-title":"Cystoid macular edema secondarytonab-paclitaxel therapy.","volume":"28","author":"Murphy","year":"2010","journal-title":"JCO"},{"key":"R5-20250909","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3129\/i11-001","article-title":"Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab.","volume":"46","author":"Baskin","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"R6-20250909","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12282-012-0373-y","article-title":"Cystoid macular edema induced by nab-paclitaxel.","volume":"22","author":"Tanaka","year":"2015","journal-title":"Breast Cancer"},{"key":"R7-20250909","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/jop.2011.0178","article-title":"Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.","volume":"29","author":"Rahman","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R8-20250909","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/eye.2012.228","article-title":"Topical dorzolamide therapy for taxane-related macular oedema.","volume":"27","author":"Ehlers","year":"2013","journal-title":"Eye (Lond)"},{"key":"R9-20250909","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3928\/23258160-20130212-02","article-title":"Cystoid macular edema secondary to nanoparticle albumin-bound paclitaxel therapy.","volume":"44","author":"Rahimy","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R10-20250909","first-page":"1","article-title":"Sub-tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound-paclitaxel (Abraxane).","volume":"2015","author":"Matsuoka","year":"2015","journal-title":"Case Rep Ophthalmol Med"},{"key":"R11-20250909","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1503\/cmaj.131080","article-title":"Cystoid macular edema associated with chemotherapy.","volume":"188","author":"Rao","year":"2016","journal-title":"CMAJ"},{"key":"R12-20250909","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/ICB.0000000000000143","article-title":"Cystoid macular edema and macular pigmentation associated with nab-paclitaxel therapy.","volume":"9","author":"Haider","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"R13-20250909","first-page":"49","article-title":"Nab-Paclitaxel induced cystoid macular edema: clinical experience with intravitreal implant of dexamethasone vs topical dorzolamide.","author":"Fenicia","year":"2014","journal-title":"Ophthalmologica"},{"key":"R14-20250909","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212733","article-title":"Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema.","volume":"2016","author":"Hassall","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R15-20250909","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CAD.0000000000000361","article-title":"Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.","volume":"27","author":"Park","year":"2016","journal-title":"Anticancer Drugs"},{"key":"R16-20250909","first-page":"599","article-title":"A case of cystoid macular edema secondary to albumin-bound paclitaxel therapy.","volume":"44","author":"Ito","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"key":"R17-20250909","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.4103\/ijo.IJO_734_19","article-title":"Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema.","volume":"67","author":"Baek","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R18-20250909","first-page":"621","article-title":"One case of binocular macular edema caused by albumin-bound paclitaxel.","volume":"55","author":"Song","year":"2019","journal-title":"Chin J Ophthalmic"},{"key":"R19-20250909","doi-asserted-by":"crossref","first-page":"100653","DOI":"10.1016\/j.ajoc.2020.100653","article-title":"Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.","volume":"18","author":"Burgos-Blasco","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R20-20250909","doi-asserted-by":"crossref","first-page":"773540","DOI":"10.3389\/fonc.2021.773540","article-title":"Intravitreal ranibizumab had limited effect on cystoid macular edema due to albumin-bound paclitaxel: a case report and literature review.","volume":"11","author":"Ye","year":"2021","journal-title":"Front Oncol"},{"key":"R21-20250909","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13256-021-02954-8","article-title":"Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.","volume":"15","author":"Otsubo","year":"2021","journal-title":"J Med Case Rep"},{"key":"R22-20250909","first-page":"272","article-title":"Cystoid macular edema secondary to albumin-bound paclitaxel therapy for pancreatic cancer.","volume":"118","author":"Shogo","year":"2021","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"R23-20250909","doi-asserted-by":"crossref","first-page":"294","DOI":"10.20344\/amp.13421","article-title":"Macular cystoid edema induced by nab-paclitaxel.","volume":"35","author":"Alves Pereira","year":"2022","journal-title":"Acta Med Port"},{"key":"R24-20250909","first-page":"377","article-title":"Nab-Paclitaxel related cystoid macular edema.","volume":"173","author":"Di Pippo","year":"2022","journal-title":"Clin Ter"},{"key":"R25-20250909","first-page":"587","article-title":"Cystoid macular edema induced by nab-paclitaxel: a case report.","volume":"38","author":"Liu","year":"2023","journal-title":"Eye Sci"},{"key":"R26-20250909","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1159\/000533999","article-title":"Cystoid macular edema following treatment with nanoparticle albumin-bound paclitaxel and Atezolizumab for metastatic breast cancer.","volume":"16","author":"Yamane","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R27-20250909","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3928\/23258160-20160126-12","article-title":"En face optical coherence tomography and optical coherence tomography angiography imaging of taxane-associated cystoid macular edema.","volume":"47","author":"Sridhar","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R28-20250909","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.clinthera.2013.10.009","article-title":"Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.","volume":"35","author":"Slingerland","year":"2013","journal-title":"Clin Ther"},{"key":"R29-20250909","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/15569527.2014.996294","article-title":"Multimodal imaging in paclitaxel-induced macular edema: the microtubule disfunction.","volume":"34","author":"Freitas-da-Costa","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"R30-20250909","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3341\/kjo.2012.26.5.394","article-title":"A case of paclitaxel-induced maculopathy treated with methazolamide.","volume":"26","author":"Koo","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"R31-20250909","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archopht.125.5.709","article-title":"Paclitaxel maculopathy.","volume":"125","author":"Joshi","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R32-20250909","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.oftal.2020.05.030","article-title":"Edema macular asociado a taxanos: presentaci\u00f3n de un caso y revisi\u00f3n de la literatura.","volume":"95","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"R33-20250909","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00417-020-04755-z","article-title":"Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings.","volume":"258","author":"Perez","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R34-20250909","first-page":"605","article-title":"Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review.","volume":"10","author":"Burgos-Blasco","year":"2020","journal-title":"Case Rep Oncol"},{"key":"R35-20250909","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1111\/aos.13219","article-title":"Paclitaxel-induced cystoid macular oedema.","volume":"96","author":"Chang","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R36-20250909","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10792-012-9558-9","article-title":"The mystery of angiographically silent macular oedema due to taxanes.","volume":"32","author":"Kuznetcova","year":"2012","journal-title":"Int Ophthalmol"},{"key":"R37-20250909","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1444-0938.2011.00672.x","article-title":"Angiographically silent cystoid macular oedema secondary to paclitaxel therapy.","volume":"95","author":"Georgakopoulos","year":"2012","journal-title":"Clin Exp Optom"},{"key":"R38-20250909","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00417-011-1642-8","article-title":"Regression of paclitaxel-induced maculopathy with oral acetazolamide.","volume":"250","author":"Meyer","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R39-20250909","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.oftal.2020.10.014","article-title":"Nepafenac for cystoid macular oedema secondary to paclitaxel.","volume":"96","author":"Tapia Quijada","year":"2021","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R40-20250909","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/ICB.0000000000000433","article-title":"Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema.","volume":"12","author":"Dwivedi","year":"2018","journal-title":"Retin Cases Brief Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:00:55Z","timestamp":1757440855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040958","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]}}}